Targets › IMP3
2 programs from 1 company in 5 trials: 4 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.
Component of the 60-80S U3 small nucleolar ribonucleoprotein (U3 snoRNP). Required for the early cleavages during pre-18S ribosomal RNA processing. (UniProt, Q9NV31)
Open in Phaseline: the race on IMP3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| West China Hospital | Engineered Mitochondrial Vaccine (IMP3-Mito) IMP3-targeting vaccine utilizing engineered mitochondrial platform | IMP3 | Phase 2 | Head and Neck Squamous Cell Carcinoma; Advanced Solid Tumor Malignancies | Dec 2026 |
| West China Hospital | IMP3-saRNA (YMN-136) Vaccine Self-amplifying RNA vaccine targeting IMP3 | IMP3 | Phase 1 | Liver Cancer; Non-Small Cell Lung Cancer; Colorectal Cancer | Feb 2028 |
Liver Cancer (1) Non-Small Cell Lung Cancer (1) Colorectal Cancer (1) Head and Neck Squamous Cell Carcinoma (1) Advanced Solid Tumor Malignancies (1)
other (1), mixed (1)
West China Hospital (2)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.